Zurex Pharma, which is developing antimicrobial products for healthcare-associated infections, has raised more than $6.2 million in equity funding, according to a regulatory filing that was made public on Thursday.
In a press release, Middleton, WI-based Zurex said the money is an “initial close of a Series C financing,” and will be used in part to support a late-stage clinical trial of its lead product candidate, ZuraPrep, a pre-surgical skin preparation. This particular investment could top out at $8 million, according to the filing.
Zurex said that some of the 26 participating investors had backed the company previously, while others were first-time investors.
Read more at Xconomy.